NCT07163507 (RICEPS-2) is a NA clinical trial of Blood sample in Lung Cancer (NSCLC), sponsored by University Hospital, Tours.

Who is sponsoring NCT07163507?

NCT07163507 is sponsored by University Hospital, Tours.

What drugs are being tested in NCT07163507?

Interventions in NCT07163507: Blood sample, sputum sample.

What condition does NCT07163507 study?

NCT07163507 studies Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell).

Is NCT07163507 still recruiting?

NCT07163507 is currently not yet recruiting. Last updated 17 March 2026.

Last reviewed 2026-03-17 · How we verify

NCT07163507: RICEPS-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immune Response to Immunotherapy in Lung Cancer: Study of Sputum and Blood Samples

Not yet recruiting NA Last updated 17 March 2026

What this trial tests

NA trial testing Blood sample in Lung Cancer (NSCLC) in 50 participants. Not yet recruiting.

Timeline

1 April 2026

Primary endpoint
1 October 2028

1 October 2028

Quick facts

Lead sponsor	University Hospital, Tours
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	50
Start date	1 April 2026
Primary completion	1 October 2028
Estimated completion	1 October 2028
Sites	1 location across France

Drugs / interventions tested

Blood sample — full drug profile →
sputum sample

Conditions studied

Lung Cancer (NSCLC) — all drugs for Lung Cancer (NSCLC) →
Lung Cancer (Non-Small Cell) — all drugs for Lung Cancer (Non-Small Cell) →

Sponsor

University Hospital, Tours

Who can join

18 and older, any sex, with Lung Cancer (NSCLC) or Lung Cancer (Non-Small Cell). Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

progression-free survival
Time frame: 12 months
progression-free survival : The primary endpoint is the association of the change, between M0 and M3, in the relative frequency of cellular actors of innate and adaptive immune responses in the sputum and blood of patients treated with ICI, with their progression-free survival (PFS) at 12 months.
Relative frequency of cellular players in innate and adaptive immune responses in the sputum of patients treated with ICI
Time frame: 6 months
The secondary endpoint is the magnitude of the association between the relative frequency of cellular players of innate and adaptive immune responses in the sputum and blood of patients treated with ICI, with their progression-free survival (PFS) at 6 months.

Sponsor's own description

Lung cancer is the leading cause of cancer-related death worldwide, with nearly 2.48 million cases and 1.8 million deaths in 2022. Despite therapeutic progress, late diagnosis and high mortality make it a major public health issue. Immune checkpoint inhibitors (ICI) such as nivolumab, pembrolizumab, and atezolizumab have improved outcomes for some patients, but only a small proportion benefit, and side effects can be severe. Research is focusing on combining ICIs with chemotherapy, radiotherapy, or other immunotherapies, but reliable biomarkers to predict responders are still lacking. The tumor microenvironment, which promotes resistance, is a promising therapeutic target. The RICEPS study (2021-2023) found specific immune cells and cytokines linked to treatment response, and the ongoing RICEPS-2 trial aims to confirm these findings in a larger group to better understand immune dynamics in lung cancer under ICI therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood sample

Trials testing the same drug.

NCT07226466 — Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer · not yet recruiting
NCT07313878 — Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Micros · NA · recruiting
NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
NCT07030205 — Resting-state Imaging and OSteoporosiS · NA · recruiting
NCT07295808 — Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN) · NA · recruiting

Other recruiting trials for Lung Cancer (NSCLC)

Currently open trials in the same condition.

NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
NCT07379476 — Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer · Phase 2 · recruiting
NCT07103395 — A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade · Phase 2 · recruiting
NCT06717295 — The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cel · recruiting
NCT07120282 — Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC · Phase 2 · recruiting

Other University Hospital, Tours trials

Trials by the same sponsor.

NCT07452978 — Propranolol for Early Secondary Prevention of Post-Traumatic Stress Disorder in Women Victims of Sexual Violence · Phase 2 · not yet recruiting
NCT07443800 — Comorbidity Between Attention Deficit Hyperactivity Disorder and Fibromyalgia · NA · not yet recruiting
NCT07251530 — Communication Enhancement Among Ventilated Patients in Intensive Care · not yet recruiting
NCT07189338 — Apneic Oxygenation With High-flow Nasal Oxygenation After Preoxygenation With Noninvasive Ventilation Before Intubation · NA · not yet recruiting
NCT07054112 — Efficacy of Live Online Course Mindfulness Program on Perceived Fatigue in Hemodialysis Patients · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07163507 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Tours
Last refreshed: 17 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07163507.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing